Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Akt1

Akt1

Brief Information

Name:Serine/threonine-protein kinase AKT
Target Synonym:EC 2.7.11,EC 2.7.11.1,PKB-ALPHA,RAC-ALPHA,AKT1m,PRKBA,CWS6,AKT,PKB alpha,RAC-alpha serine/threonine-protein kinase,AKT1,AKT Serine/Threonine Kinase 1,Protein Kinase B Alpha,PKB,Serine-Threonine Protein Kinase,Rac Protein Kinase Alpha,Proto-oncogene c-Akt,Protein kinase B,RAC,RAC-PK-alpha,V-Akt Murine Thymoma Viral Oncogene-Like Protein 1,V-Akt Murine Thymoma Viral Oncogene Homolog 1,EC:2.7.11.1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AK1-H5283 Human Human Akt1 Protein, His,Strep II Tag
AK1-H5283-structure
AK1-H5283-sds

Synonym Name

AKT1,PKB,RAC,RAC-PK-alpha,PKB alpha

Background

RAC-alpha serine/threonine-protein kinase (AKT1) is also known PKB, Protein kinase B alpha, PKB alpha, Proto-oncogene c-Akt and RAC-PK-alpha, which belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family and RAC subfamily and is expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase).

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Hu-7691 Hu7691 Phase 1 Clinical Zhejiang University Neoplasms Details
CMX-2043 LIP-EA; CMX-2043; R-LIP-EA-OH Phase 2 Clinical Ischemix Reperfusion Injury; Angina, Unstable; Coronary Artery Disease Details
TAS-117 TAS-117 Phase 2 Clinical Solid tumours; Neoplasms Details
Selumetinib sulfate/MK-2206 Phase 2 Clinical Astrazeneca Plc, Merck & Co Inc Triple Negative Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Oxysterols (Intsel Chimos) Clinical Centre National De La Recherche Scientifique (Cnrs) Glioma Details
GSK-690693 GSK-690693 Phase 1 Clinical Glaxosmithkline Plc Neoplasms; Lymphoma Details
CLR-124 CLR-124; [124I]NM-404; NM-404-[124I]; [124I]CLR-1404; CLR-1404-[124I] Phase 2 Clinical University Of Michigan Glioblastoma; Diagnostic agents Details
Triciribine Phosphate API-2; TCN-P; PTX-002; VQD-002; NSC-154020; NSC-280594; VQD-002-ORAL Phase 2 Clinical National Cancer Institute Ovarian Neoplasms; Leukemia; Hematologic Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute Details
Uprosertib GSK-795; GSK-2141795; GSK-2141795C Phase 2 Clinical Novartis Pharma Ag, National Cancer Institute, Glaxosmithkline Plc Solid tumours; Neoplasms; Multiple Myeloma; Breast Neoplasms; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
Uprosertib/Trametinib Dimethyl Sulfoxide Phase 2 Clinical Novartis Pharma Ag Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
HZB0071 HZB-0071 Phase 1 Clinical Wuxi Apptec Co Ltd, Heilongjiang Zbd Pharmaceutical Co Ltd Neoplasms Details
TIC-10 ONC201 - Oncoceutics; ONC201/TIC10; NSC-350625; TIC-10; ONC-201 Phase 2 Clinical Oncoceutics Glioblastoma; Thalamic Diseases; Triple Negative Breast Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
RX-0301 RX-0201 nanoliposomal; RX-0201 Nano; RX-0201-N; RX-0301; RX-0201; WGI-0301 Phase 1 Clinical Rexahn Pharmaceuticals Liver Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms Details
Iopofosine I-131 HOT; CLR1404 I-131; I-131-CLR1404; (131)I-NM 404; 131I-NM-404; CLR-131; (131)I-CLR1404; NM404 Phase 2 Clinical University Of Michigan Rhabdomyosarcoma; Solid tumours; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Central Nervous System Neoplasms; Neuroblastoma; Brain Neoplasms; Sarcoma, Ewing; Osteosarcoma; Lymphoma, Mantle-Cell; Diffuse Intrinsic Pontine Glioma; Lymphoma; Waldenstrom Macroglobulinemia; Glioma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Honokiol HU-002; JRF-101 Phase 1 Clinical Anacor Pharmaceuticals Non-alcoholic Fatty Liver Disease; Gingival Diseases; Carcinoma, Non-Small-Cell Lung Details
Miransertib MK-7075; ARQ-092 Phase 2 Clinical Arqule Ovarian Neoplasms; Proteus Infections; Solid tumours; Growth Disorders; Lymphoma; Proteus Syndrome; Endometrial Neoplasms Details
Capivasertib AZD-5363 Phase 3 Clinical Astrazeneca Pharmaceutical Co Ltd Solid tumours; Ovarian Neoplasms; Hematologic Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Afuresertib ASB-183; GSK-2110183B; GSK-2110183C; GSK-21110183; LAE-002; GSK-2110183 Phase 2 Clinical Glaxosmithkline Plc, Novartis Pharma Ag Solid tumours; Ovarian Neoplasms; Hematologic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Histiocytosis, Langerhans-Cell; Peritoneal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell Details
Ipatasertib Dihydrochloride RG-7440; GCD-0068; GDC-0068; RO-5532961 Phase 3 Clinical Array Biopharma, F. Hoffmann-La Roche Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Hepatic Insufficiency; Neoplasms, Unknown Primary; Gastrointestinal Neoplasms; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message